454O A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)

C Guo,I Colombo,I Figueiredo,S Jain,M ,K Chandran,M Parmar,A Sharp,A Stathis,A Alimonti,C Yap,U Vogl,J.S De Bono,J Rekowski,A Turner,C Tiu,H.C Badham,R.E Matthews,A Paschalis,F Raynaud

doi:10.1016/j.annonc.2022.07.583

454O A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)

C Guo, I Colombo + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.583

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2022
Citations: 4	License type: publisher-specific-oa

Affiliation: Institute of Cancer Research, Royal Marsden Hospital, Prostate Cancer Research, Ospedale Regionale di Bellinzona e Valli, Belfast Health and Social Care Trust, University of Ulster, Belfast City Hospital

#Selective CXCR2 Antagonist #Metastatic Castration Resistant Prostate Cancer + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Tumour-infiltrating myeloid cells drive mCRPC growth and therapeutic resistance, in part through IL-23 and NRG1 secretion. Inhibition of myeloid infiltration by disrupting the CXCR2 receptor axis can reverse ENZA resistance in PC models. AZD5069 is a selective CXCR2 antagonist.

Full Text